Diabetes Care, Vol 17, Issue 6 531-534, Copyright © 1994 by American Diabetes Association

ARTICLES

The role of growth hormone in the development of diabetic retinopathy

AA Alzaid, SF Dinneen, LJ Melton and RA Rizza
Department of Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

OBJECTIVE--To determine the role of growth hormone (GH) in the development of diabetic retinopathy. RESEARCH DESIGN AND METHODS--Medical records of 1,423 patients who had undergone insulin tolerance tests (1976-1991) at the Mayo Clinic were examined, and diabetic subjects were identified as either GH-deficient (GH increment after hypoglycemia < 5 micrograms/L and peak < 10 micrograms/L) or GH-sufficient. Prevalence of retinopathy was determined in these cases and in a cohort group of diabetic subjects selected to match the GH-deficient cases. These control patients (32 cases) were selected from medical records of individuals who had received medical care at Mayo during the same interval but who had not undergone insulin tolerance testing. RESULTS--Twenty-four patients with diabetes were identified, of whom 16 were GH-deficient and 8 GH-sufficient. Despite comparable age, duration of diabetes, and metabolic control, the prevalence of diabetic retinopathy in the GH-deficient group (2 of 16; 12.5%) was less (P < 0.05) than that observed in the GH-sufficient group (5 of 8; 62.5%). Prevalence in the GH-deficient group also was lower than that observed in the cohort control group (15 of 32, 47%). CONCLUSIONS--These data strongly suggest that GH contributes to the development of diabetic retinopathy in humans.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Ostergard, K. B. Degn, M.-A. Gall, R. D. Carr, J. D. Veldhuis, M. K. Thomsen, R. A. Rizza, and O. Schmitz The Insulin Secretagogues Glibenclamide and Repaglinide Do Not Influence Growth Hormone Secretion in Humans but Stimulate Glucagon Secretion during Profound Insulin Deficiency J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 297 - 302. [Abstract] [Full Text] [PDF]

				R. Amin, C. Schultz, K. Ong, J. Frystyk, R. N. Dalton, L. Perry, H. Orskov, and D. B. Dunger Low IGF-I and Elevated Testosterone During Puberty in Subjects With Type 1 Diabetes Developing Microalbuminuria in Comparison to Normoalbuminuric Control Subjects: The Oxford Regional Prospective Study Diabetes Care, May 1, 2003; 26(5): 1456 - 1461. [Abstract] [Full Text] [PDF]

				S. Q. DOI, T. A. JACOT, D. F. SELLITTI, P. HIRSZEL, M. H. HIRATA, G. E. STRIKER, and L. J. STRIKER Growth Hormone Increases Inducible Nitric Oxide Synthase Expression in Mesangial Cells J. Am. Soc. Nephrol., August 1, 2000; 11(8): 1419 - 1425. [Abstract] [Full Text]

				D. Blank, M. Riedl, A. Reitner, C. Schnack, G. Schernthaner, M. Clodi, H. Frisch, and A. Luger Growth Hormone Replacement Therapy Is Not Associated with Retinal Changes J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 634 - 636. [Abstract] [Full Text]

				P. F. Catalina, F. Mallo, M. A. Andrade, R. V. García-Mayor, and C. Diéguez Growth Hormone (GH) Response to GH-Releasing Peptide-6 in Type 1 Diabetic Patients with Exaggerated GH-Releasing Hormone-Stimulated GH Secretion J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3663 - 3667. [Abstract] [Full Text]

				E. A. Koller, L. Green, J. M. Gertner, M. Bost, and S. N. Malozowski Retinal Changes Mimicking Diabetic Retinopathy in Two Nondiabetic, Growth Hormone-Treated Patients J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2380 - 2383. [Abstract] [Full Text]

				T. Fulcher, M. Griffin, S. Crowley, R. Firth, R. Acheson, and N. O'Meara Diabetic retinopathy in Down's syndrome Br. J. Ophthalmol., April 1, 1998; 82(4): 407 - 409. [Abstract] [Full Text]